<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00303537</url>
  </required_header>
  <id_info>
    <org_study_id>AkerU3</org_study_id>
    <nct_id>NCT00303537</nct_id>
  </id_info>
  <brief_title>Metformin in Non-Alcoholic Fatty Liver Disease</brief_title>
  <official_title>Double Blind, Randomized, Placebo Controlled Trial With Metformin in Non-Alcoholic Fatty Liver Disease (NAFLD)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Hospital, Aker</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Merck Sharp &amp; Dohme Corp.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>University Hospital, Aker</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The study evaluates the use of the antidiabetic medicine metformin in nonalcoholic fatty&#xD;
      liver disease.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Nonalcoholic fatty liver disease (NAFLD) is a prevalent disorder associated with insulin&#xD;
      resistance. Metformin is a drug that has been used for several decades in the treatment of&#xD;
      diabetes mellitus. Metformin is known to improve insulin sensitivity. Some authors have&#xD;
      reported beneficial effects of metformin in NAFLD, others have not been able to reproduce&#xD;
      these findings. Only a few randomized controlled studies have been published so far, and&#xD;
      there is still need for controlled trials with sufficient power to assess the efficacy of&#xD;
      metformin in this condition.&#xD;
&#xD;
      The aim of this study is to see whether treatment with metformin for 26 weeks results in&#xD;
      reduction of liver steatosis (primary endpoint) and reduction in grade of inflammation in&#xD;
      those with non-alcoholic steatohepatitis (NASH) (secondary endpoint).&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Active, not recruiting</last_known_status>
  <start_date>November 2004</start_date>
  <completion_date type="Anticipated">June 2008</completion_date>
  <phase>Phase 2/Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Grade of steatosis as judged by repeat biopsy</measure>
    <time_frame>6 mo</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Grade of necroinflammation as judged by repeat biopsy</measure>
    <time_frame>6 mo</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Liver density obtained by computer scan</measure>
    <time_frame>6 mo</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Serum alanine transaminase (ALAT)</measure>
    <time_frame>6 mo</time_frame>
  </secondary_outcome>
  <enrollment type="Anticipated">90</enrollment>
  <condition>Fatty Liver</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>metformin</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Histologically proven NAFLD less than 18 months prior to inclusion. For those with&#xD;
             pure steatosis, ALAT or aspartate aminotransferase (ASAT) must be elevated above the&#xD;
             upper limits of normal, and impaired glucose tolerance or diabetes mellitus type 2&#xD;
             must be present.&#xD;
&#xD;
          -  Body weight within +/- 5 kg compared with the weight at the time of biopsy.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Treatment for more than 1 week with metformin or glitazones the last 6 months before&#xD;
             inclusion.&#xD;
&#xD;
          -  Treatment with insulin.&#xD;
&#xD;
          -  Hypersensitivity to metformin.&#xD;
&#xD;
          -  Treatment with cimetidine.&#xD;
&#xD;
          -  Heart failure requiring pharmacological treatment.&#xD;
&#xD;
          -  Coronary heart disease (New York Heart Association [NYHA] class 3 or 4).&#xD;
&#xD;
          -  Chronic obstructive lung disease (moderate or severe).&#xD;
&#xD;
          -  Breast-feeding or pregnant.&#xD;
&#xD;
          -  Metabolic acidosis.&#xD;
&#xD;
          -  Renal failure (male [♂]: creatinine &gt; 135 micromol/L, female [♀] &gt; 110 micromol/L).&#xD;
&#xD;
          -  Average alcohol consumption &gt; 24 g/day the last year.&#xD;
&#xD;
          -  Serum ALAT or serum ASAT &gt; 5 x upper limit of normal (ULN) at screening.&#xD;
&#xD;
          -  Cirrhosis.&#xD;
&#xD;
          -  Platelets &lt; 100 000.&#xD;
&#xD;
          -  Haemochromatosis.&#xD;
&#xD;
          -  Alfa-1-antitrypsin-deficiency.&#xD;
&#xD;
          -  Wilson's disease.&#xD;
&#xD;
          -  Thyroid dysfunction (0.2 mU/L &lt; thyroid stimulating hormone [TSH] &lt; 5.0 mU/L).&#xD;
&#xD;
          -  Chronic infection with hepatitis B or C virus or HIV.&#xD;
&#xD;
          -  Autoimmune hepatitis (antinuclear antibodies [ANA] &gt; 1/256 or smooth muscle antibodies&#xD;
             [SMA] &gt; 1/128).&#xD;
&#xD;
          -  Primary biliary cirrhosis (antimitochondrial antibodies [AMA] &gt; 1/64).&#xD;
&#xD;
          -  Primary sclerosing cholangitis.&#xD;
&#xD;
          -  Previous participation in another clinical trial the last 6 months.&#xD;
&#xD;
          -  Legal incapability.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Kaare Birkeland, Prof./Ph.D</last_name>
    <role>Study Chair</role>
    <affiliation>Aker University Hospital, Oslo, Norway</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Zbigniew Konopski, Cons./Ph.D</last_name>
    <role>Study Chair</role>
    <affiliation>Aker University Hospital, Oslo, Norway</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Kristian Bjøro, Cons./Ph.D</last_name>
    <role>Study Chair</role>
    <affiliation>Rikshospitalet-Radiumhospitalet, Oslo, Norway</affiliation>
  </overall_official>
  <overall_official>
    <last_name>John W Haukeland, Physician</last_name>
    <role>Principal Investigator</role>
    <affiliation>University Hospital, Aker</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Haukeland Universitetssykehus</name>
      <address>
        <city>Bergen</city>
        <country>Norway</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Aker University Hospital</name>
      <address>
        <city>Oslo</city>
        <country>Norway</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Akershus University Hospital</name>
      <address>
        <city>Oslo</city>
        <country>Norway</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitetssykehuset i Nord-Norge</name>
      <address>
        <city>Tromsø</city>
        <country>Norway</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Norway</country>
  </location_countries>
  <verification_date>June 2007</verification_date>
  <study_first_submitted>March 16, 2006</study_first_submitted>
  <study_first_submitted_qc>March 16, 2006</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 17, 2006</study_first_posted>
  <last_update_submitted>June 29, 2007</last_update_submitted>
  <last_update_submitted_qc>June 29, 2007</last_update_submitted_qc>
  <last_update_posted type="Estimate">July 2, 2007</last_update_posted>
  <keyword>hepatitis</keyword>
  <keyword>metformin</keyword>
  <keyword>non-alcoholic fatty liver (NAFLD)</keyword>
  <keyword>non-alcoholic steatohepatitis (NASH)</keyword>
  <keyword>Nonalcoholic fatty liver disease</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Liver Diseases</mesh_term>
    <mesh_term>Fatty Liver</mesh_term>
    <mesh_term>Non-alcoholic Fatty Liver Disease</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Metformin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

